NFE2L2 and ovarian cancer: Sphingosine kinase 1 (SPHK1) drives NRF2 transcription and suppresses ferroptosis via NF-κB p65 activation, thereby conferring resistance to olaparib in ovarian cancer cells (Teng et al., 2025).